On July 15, 2026, US Defense Secretary Pete Hegseth announced that the military will begin annual testosterone screening for service members aged 30 and older, with those under 30 allowed to opt in voluntarily. Al Jazeera

Hegseth shared the news in a video posted on X, formerly Twitter. The screening will be folded into the periodic health assessment that troops already complete each year. Any treatment that follows, including testosterone replacement therapy (TRT), stays the service member's own decision. Al Jazeera

Hegseth framed the initiative as "not about artificial enhancement" but about "restoring and optimising your natural capabilities, protecting your longevity, ensuring you have the biological foundation required to sustain the fight." He said the screening is meant to address what the military calls "Operator Syndrome," a cluster of physical and cognitive symptoms linked to the prolonged stress of combat deployments. Al Jazeera; US Department of Defense

The policy has a legislative origin. The Fiscal Year 2025 National Defense Authorization Act, the annual law that sets the Pentagon's budget and policy priorities, included a provision requiring the defense secretary to brief Congress on treatments for low testosterone and existing screening protocols. Al Jazeera

Lawmakers have pushed back. Senator Tammy Duckworth, a retired Army National Guard lieutenant colonel and combat veteran, called the screening "like gender-affirming care to me." Representative Chrissy Houlahan, who also served in the Air Force, said the announcement "proves that Secretary Hegseth takes direction from the far corners of the manosphere." Al Jazeera

Both Duckworth and Houlahan called for hormone screening to be extended to women in uniform, pointing to elevated infertility rates among military personnel. Al Jazeera

The broader context here involves a familiar tension in military medicine: the balance between force readiness and individual medical autonomy. By embedding testosterone screening within an existing annual check-up, the Pentagon is treating hormonal health as a routine measure of operational fitness. Hegseth's language, which casts hormone levels as part of "the biological foundation required to sustain the fight," positions this as a question of how long a service member can keep performing, not simply personal wellness.

The voluntary treatment element introduces uncertainty. If a service member screens low but declines TRT, there is no stated career penalty, at least for now. Military medicine has long navigated the boundary between fitness standards and personal medical decisions. Whether routine hormone data eventually feeds into fitness evaluations, deployment eligibility, or command decisions is an open institutional question.

The legislative path also matters. The NDAA provision did not mandate screening; it asked for a briefing. Hegseth's announcement turns a congressional information request into an actual policy, which gives lawmakers an opening to scrutinize implementation, including whether the program is medically justified or driven by ideology, as Duckworth and Houlahan suggest.

Their call to extend screening to women, grounded in military infertility data, shifts the debate from a critique of Hegseth's priorities to a demand for parity in force-wide hormonal health. If that demand gains traction, it could expand the policy into a broader initiative covering both men and women.

What comes next will depend on the specifics: screening thresholds, referral pathways, data privacy protections, and how the system handles the opt-in tier for under-30s. Congress will likely press for those details in oversight hearings. For now, the policy is announced but not yet in operation.